SCP Scope Fluidics S.A.

GPW · PL · Healthcare · Diagnostics & Research · scopefluidics.com

120.00PLN0.00%Mkt Cap: 96.29M $P/E: —Today

Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. It offers BacterOMIC, an antibiotic susceptibility testing. …

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc Common Stock

$242.11BUSDP/E 35.5

DHR

Danaher Corporation Common Stock

$150.48BUSDP/E 38.2

NTRA

Natera, Inc. - Common Stock

Agilent Technologies, Inc. Common Stock

$47.30BUSDP/E 33.1

IQV

IQVIA Holdings, Inc. Common Stock

$42.50BUSDP/E 32.2

WAT

Waters Corporation Common Stock

$41.75BUSDP/E 107.4

ILMN

Illumina, Inc. - Common Stock

$41.23BUSDP/E 50.8

IDXX

IDEXX Laboratories, Inc. - Common Stock

$40.89BUSDP/E 36.4

MTD

Mettler-Toledo International, Inc. Common Stock

$29.78BUSDP/E 34.0

DGX

Quest Diagnostics Incorporated Common Stock

$25.75BUSDP/E 25.0

Labcorp Holdings Inc. Common Stock

$25.02BUSDP/E 25.5

Guardant Health, Inc. - Common Stock

$23.86BUSD

RVTY

Revvity, Inc. Common Stock

$16.91BUSDP/E 72.5

MEDP

Medpace Holdings, Inc. - Common Stock

$16.73BUSDP/E 35.2

ERF

Eurofins Scientific SE

$14.05BUSDP/E 26.2

CRL

Charles River Laboratories International, Inc. Common Stock

$13.85BUSD

ICLR

ICON plc - Ordinary Shares

Qiagen N.V. Common Shares

$9.24BUSDP/E 22.7

Key Statistics

Company

Market Cap96.29M USD

Enterprise Value—

Revenue (TTM)-130.94K USD

Gross Profit-921.36K USD

Net Income (TTM)-11.74M USD

Revenue/Share-0.15 PLN

Last Price120.00 PLN

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees86

CountryPL

SectorHealthcare

IndustryDiagnostics & Research

ISINPLSCPFL00018

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S-735.38

P/B2.74

EPS (TTM)-16.97

EPS (Forward)—

52W Range

109.0015% of range182.20

52W High182.20 PLN

52W Low109.00 PLN

Profitability

Gross Margin-3638.00%

Oper. Margin-36725.00%

EBITDA Margin0.00%

Profit Margin-46364.00%

ROE-28.54%

ROA-23.66%

Growth

Revenue Growth-95.10%

Earnings Growth—

Cash Flow & Leverage

Operating CF-11.68M USD

CapEx (TTM)3.39M USD

FCF Margin31070.96%

FCF Yield-42.25%

Net Debt—

Net Debt/EBITDA—

Balance Sheet

Debt/Equity0.01

Current Ratio10.52

Quick Ratio—

Book Value/Sh43.83 PLN

Cash/Share—

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 PLN

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div DateMar 24, 2023

Pay Date—

Analyst Consensus

Rating—

Target (Mean)223.90 PLN

Upside (mean)+86.6%

Target Range223.90 PLN – 223.90 PLN

# Analysts1

Ownership

Shares Out.3.17M

Float2.34M

Insiders22.85%

Institutions21.74%

Technical

SMA 50129.80 (-7.6%)

SMA 200133.07 (-9.8%)

Beta—

S&P 52W Chg14.58%

Avg Vol (30d)1.18K

Avg Vol (10d)1.48K

Technical Indicators

RSI (14)43.6

MACD-0.1141

MACD Signal0.8129

MACD Hist.-0.9270

BB Upper137.37 PLN

BB Middle124.49 PLN

BB Lower111.61 PLN

BB Width20.70%

ATR (14)5.112 PLN

Vol Ratio (20d)0.31x